Industry and Geographic Information

3 Months Ended

Mar. 31, 2022

Industry And Geographic Information [Abstract]

The Company operates in one reportable segment. Sales to customers outside of the United States represented $95.1 million (9%) and $86.6 million (23%) of total revenues for the three months ended March 31, 2022 and 2021, respectively. As of March 31, 2022 and December 31, 2021, net accounts receivable due from foreign customers were $70.3 million and $53.5 million, respectively. For the three months ended March 31, 2022 and 2021, sales of COVID-19 products accounted for 83% and 72% of total revenue, respectively. For the three months ended March 31, 2022 and 2021, sales of influenza products accounted for 9% and 4% of total revenue, respectively.

The Company had sales to individual customers in excess of 10% of total revenues, as follows:


	Three Months Ended March 31,
	2022		2021
Customer:
A	38	%	—	%
B	14	%	22	%
C	8	%	12	%

Total:	60	%	34	%

As of March 31, 2022 and December 31, 2021, net accounts receivable from customers with balances due in excess of 10% of total accounts receivable totaled $468.2 million and $267.3 million, respectively.

Consolidated total revenues by product category for the three months ended March 31, 2022 and 2021 were as follows (in thousands):


	Three Months Ended March 31,
		2022		2021
Rapid Immunoassay		$	892,810	$	237,670
Cardiometabolic Immunoassay		50,153		66,552
Molecular Diagnostic Solutions		45,989		60,263
Specialized Diagnostic Solutions		13,307		10,853
Total revenues		$	1,002,259	$	375,338